Rituximab. The correct answer is C: Topical glucocorticoids. This question can be found in MKSAP 17 in the Hematology and Oncology section, item 118.
Residency: University of Arizona, 1991 (chief resident, 1992). Fellowship: University of Arizona (general medicine, medical oncology, NIH cancer prevention and etiology). ... Current patient care activities: Medical oncology/women's cancer, 25%. Current
Despite the challenges of microbiome research, recent years have brought evidence in several fields such as infectious diseases, endocrinology, pharmacology, and oncology, Dr. ... In oncology, two basic science studies published in 2015 by Science found
Dr. Burkholder later completed a senior fellowship in oncology and served as a founder and acting director of the Mountain States Tumor Institute.
And there must be more applications for this knowledge. I'm picturing snarky oncology residents making up mean nicknames for the quiet new intern— Bobximab, perhaps?
department of general oncology at the University of Texas M.D.
One review, published last year in Annals of Oncology, analyzed 25 randomized controlled trials and found that more than 85% of the trials stopped in a three-year period were used
Flaig, MD, assistant professor in the division of medical oncology at the University of Colorado Denver and the University of Colorado Health Sciences Center, said that the issue at the heart
Dr. Kaelin came to Dana-Farber Cancer Institute in 1987 as a medical oncology fellow with the intention of becoming a clinical oncologist.
This is not news in oncology; the concept has been understood for years as it applies to "liquid" tumors like leukemia, as he points out. ... Maybe the median doesn't matter so much as we'd thought. Here's a retro idea: In 2012, maybe the ideal and most